Phagenesis: A Game-Changer in Swallowing Dysfunction Treatment

Manchester-based company Phagenesis has secured a hefty $42M in Series D financing to further develop its innovative neurostimulation system for treating swallowing dysfunction. Led by EQT Life Sciences and Sectoral Asset Management, with new investors British Patient Capital, Northern Gritstone, and Aphelion on board, the funding will fuel the company's expansion efforts, particularly in the United States where their FDA-approved Phagenyx® system is gaining traction. Co-founded by Dr. Conor Mulrooney and Professor Shaheen Hamdy, Phagenesis aims to revolutionize the treatment of neurogenic dysphagia using pharyngeal electrical stimulation (PES). This technology targets and restores the neurological components of swallowing coordination disrupted by brain injuries or prolonged mechanical ventilation. CEO Reinhard Krickl envisions a future where their therapy helps millions of patients suffering from swallowing disorders, reducing healthcare costs and improving outcomes. With a focus on commercialization, clinical trials, and regulatory activities, Phagenesis is poised to make a significant impact in the medical device market, addressing a critical unmet need in healthcare.